Ossium Health, a San Francisco, CA-based therapeutics company leveraging stem cell science to improve treatment for patients with blood and immune diseases, raised $63m in Series B funding.
The round was co-led by General Catalyst and Vivo Capital with participation from previous investors First Round Capital, Manta Ray Ventures, and XYZ Capital.
Founded in 2016 and run by its Co-Founder, President & CEO Kevin Caldwell, and its Co-Founder, EVP & Chief Science Officer Erik Woods, Ossium Health is a therapeutics company that leverages its deceased donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening blood and immune diseases.
The funds will support an initial suite of clinical trials to use donor-matched hematopoietic stem cells to re-educate the immune systems of organ recipients to accept donor organs, to deploy the anti-inflammatory properties of mesenchymal stem cells to promote healing in patients with fistulizing Crohn’s disease, and to reset the malignant immune systems of hard to match blood cancer patients using bone marrow transplants from organ donors.
FinSMEs
19/03/2021